| 000 | 01845 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250516104730.0 | ||
| 264 | 0 | _c20130117 | |
| 008 | 201301s 0 0 eng d | ||
| 022 | _a1476-5454 | ||
| 024 | 7 |
_a10.1038/eye.2012.174 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aFung, A T | |
| 245 | 0 | 0 |
_aPilot study to evaluate the role of high-dose ranibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with persistent/recurrent macular fluid <30 days following treatment with intravitreal anti-VEGF therapy (the LAST Study). _h[electronic resource] |
| 260 |
_bEye (London, England) _cSep 2012 |
||
| 300 |
_a1181-7 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAngiogenesis Inhibitors _xadministration & dosage |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Humanized _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIntravitreal Injections |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aPilot Projects |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 | _aRanibizumab |
| 650 | 0 | 4 | _aSingle-Blind Method |
| 650 | 0 | 4 |
_aSubretinal Fluid _xmetabolism |
| 650 | 0 | 4 | _aTomography, Optical Coherence |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aVascular Endothelial Growth Factor A _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aVisual Acuity _xphysiology |
| 650 | 0 | 4 |
_aWet Macular Degeneration _xdiagnosis |
| 700 | 1 | _aKumar, N | |
| 700 | 1 | _aVance, S K | |
| 700 | 1 | _aSlakter, J S | |
| 700 | 1 | _aKlancnik, J M | |
| 700 | 1 | _aSpaide, R S | |
| 700 | 1 | _aFreund, K B | |
| 773 | 0 |
_tEye (London, England) _gvol. 26 _gno. 9 _gp. 1181-7 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/eye.2012.174 _zAvailable from publisher's website |
| 999 |
_c22012321 _d22012321 |
||